Quarterly Business Update Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) is pleased to provide the following update on its business activities for the three-month period to 31 December 2018. Collaboration agreement signed with US big pharma: deal with Janssen Research & Development, LLC to accelerate diabetic kidney disease and heart disease drug discovery using PromarkerD Production of PromarkerD kit version completed: new PromarkerD immunoassay results presented at 18th Diabetes Technology Meeting in USA Record quarterly revenue: continued strength from Analytical Services contracts resulted in quarterly revenue increasing 42% to exceed $0.5 million PromarkerD test to enter Europe: licence deal with Patia Europe to see PromarkerD test available in Spain Dual technology platform provides more licensing opportunities for PromarkerD R&D for new diagnostic tests: proof of concept studies on-going for endometriosis and Giardia
- Forums
- ASX - By Stock
- Ann: Appendix 4C - December 2018 Quarterly Report
Quarterly Business Update Medical technology company Proteomics...
-
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PIQ (ASX) to my watchlist
|
|||||
Last
63.0¢ |
Change
-0.070(10.0%) |
Mkt cap ! $82.53M |
Open | High | Low | Value | Volume |
70.5¢ | 71.0¢ | 60.0¢ | $882.4K | 1.345M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 500 | 62.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
63.0¢ | 3952 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 500 | 0.625 |
2 | 19129 | 0.620 |
2 | 2170 | 0.615 |
2 | 104000 | 0.610 |
1 | 13500 | 0.605 |
Price($) | Vol. | No. |
---|---|---|
0.630 | 3952 | 1 |
0.635 | 75122 | 2 |
0.640 | 2528 | 1 |
0.650 | 9298 | 1 |
0.655 | 2464 | 1 |
Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
Featured News
PIQ (ASX) Chart |